Home/Iovance Biotherapeutics/Ryan Maynard

RM

Ryan Maynard

Chief Financial Officer

Iovance Biotherapeutics

Therapeutic Areas

Oncology Solid Tumors

Iovance Biotherapeutics Pipeline

Drug	Indication	Phase
Amtagvi (lifileucel)	Advanced Melanoma (post-anti-PD1)	Approved
Lifileucel	Advanced Non-Small Cell Lung Cancer (NSCLC)	Phase 2
TIL + Pembrolizumab	Advanced Front-line Melanoma	Phase 3

Leadership Team at Iovance Biotherapeutics

Interim President and Chief Executive Officer

Ibrahim El-Houssieny

Chief Commercial Officer

Michael Weickert

Chief Technology Officer

Jean-Marc Bellemin

Chief Medical Officer

View full Iovance Biotherapeutics profile